Clinical Trials Logo

Filter by:
NCT ID: NCT00385463 Withdrawn - Asthma Clinical Trials

Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Receiving Advair Diskus or Placebo

Start date: April 2006
Phase: N/A
Study type: Interventional

The four respiratory drugs being researched in this study have been approved by the US Food and Drug Administration (FDA) and are currently available by prescription at your drug store. One of the drugs is for the treatment of asthma alone, one is for treatment of SAR alone, and one is for treatment of both SAR and asthma. In addition, you will also receive one asthma rescue drug (albuterol) that is to be used for any breakthrough asthma symptoms that you may experience throughout the study. The purpose of this study is to see how well your asthma and SAR are controlled when taking one of the medicine combinations

NCT ID: NCT00382837 Withdrawn - Clinical trials for Systemic Lupus Erythematosus

Study of Epratuzumab in Systemic Lupus Erythematosus

Start date: January 2007
Phase: Phase 3
Study type: Interventional

Epratuzumab is an investigational antibody designed to help treat SLE. The purpose is to evaluate safety and long term efficacy in concert with standard SLE treatments

NCT ID: NCT00382447 Withdrawn - Asthma Clinical Trials

Breath Actuated Nebulizer Study Protocol

Start date: October 2006
Phase: N/A
Study type: Interventional

Comparison of the researchers' standard nebulizer and a breath actuated nebulizer to examine if breathing medication can be delivered more quickly and as effectively or more effectively than the standard nebulizer.

NCT ID: NCT00382382 Withdrawn - Autistic Disorder Clinical Trials

Diffusion Tensor Imaging in Autism

Start date: July 2008
Phase: N/A
Study type: Interventional

Using a new and more detailed approach to diffusion tensor imaging (DTI) recently developed in our lab, the investigators hope to learn more about irregularities in the brain that are related to autism. The investigators are especially interested in brain regions that contribute to repetitive behaviors in children with autism. Repetitive behaviors include stereotyped motor movements (hand-flapping), self-injurious behaviors (head hitting), compulsions (lining up toys), insistence on things staying the same, and difficulty with change. These behaviors often interfere with learning, can disrupt daily functioning, and can lead to other behavioral problems. Two specific aims will be accomplished: Aim 1: To examine the integrity of white matter pathways in high functioning autistic children. The investigators hypothesize that autism is associated with specific white matter abnormalities in the cerebellum and other motor circuits. Additionally, the investigators expect to confirm and expand on previous reports of cerebral abnormalities by using newly developed DTI methods. Aim 2: To determine whether there is a relationship between white matter abnormalities and the occurrence of restricted repetitive behaviors in children with autism. The investigators hypothesize that differences in the occurrence and type of restricted repetitive behaviors between autistic individuals are correlated with specific regional white matter abnormalities. Results from the proposed experiments should contribute to current knowledge of brain abnormalities in autism and their relationship to restricted repetitive behaviors, and may be relevant to understanding the mechanisms underlying motor deficits in this disorder.

NCT ID: NCT00382330 Withdrawn - Vulvar Cancer Clinical Trials

Chemoprevention of Cancer in the Lower Female Genital Tract: The Antineoplastic Activity of the Fungicide Ciclopirox.

Start date: n/a
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if regular and daily repeated application of the ciclopirox lotion to vulva will make the precancerous lesion(s) shrink or even disappear.

NCT ID: NCT00381225 Withdrawn - Clinical trials for Head and Neck Neoplasia

Feasibility of Ultra-sound Guided Radiofrequency Ablation in the Management of Head and Neck Neoplasia.

Start date: November 2006
Phase: N/A
Study type: Interventional

To study the feasibility of Radiofrequency ablation (RFA) via ultrasound guidance in the management of head and neck neoplasia.

NCT ID: NCT00380835 Withdrawn - Clinical trials for Metastatic Breast Cancer

Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer

Start date: n/a
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the incidence of cardiac toxicity of amrubicin when administered to patients with metastatic breast cancer.

NCT ID: NCT00380458 Withdrawn - Clinical trials for Sleep Apnea, Obstructive

Study to Evaluate Recovery From Postoperative Pain After Sleep Apnea Surgery

Start date: n/a
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess whether tonsillectomy and UPPP performed using the study device to treat Obstructive Sleep Apnea (OSA) symptoms in adults is associated with less postoperative pain during the 21-day postoperative recovery period compared to electrocautery dissection.

NCT ID: NCT00378300 Withdrawn - Atopic Dermatitis Clinical Trials

The Effects of Probiotics in Atopic Dermatitis

Start date: July 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to study the clinical effects of taking probiotics in patients who have moderate to severe atopic dermatitis. There has been several studies showing improvement in the severity of atopic dermatitis after taking probiotics. The mechanism of this improvement is currently unknown. We propose that probiotics improve atopic dermatitis by stimulating, or increasing, the activity of a special type of cell called the T Regulatory cell--which can suppress the activity of allergic disease.

NCT ID: NCT00378235 Withdrawn - Clinical trials for Recurrent Malignant Glioma

Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma

Start date: n/a
Phase: Phase 1/Phase 2
Study type: Interventional

IL13-PE38QQR is an oncology drug product consisting of IL13 (interleukin-13) and PE38QQR (a bacteria toxin). IL3-PE38QQR is a protein that exhibits cell killing activity against a variety of IL13-receptor positive tumor cell lines indicating that it may show a therapeutic benefit. In reciprocal competition experiments, the interaction between IL13-PE38QQR and the IL13 receptors was shown to be highly specific for human glioma cells.